Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History OPK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics OPK

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Opko Health Inc

OPK
Current price
1.36 USD -0.01 USD (-0.73%)
Last closed 1.36 USD
ISIN US68375N1037
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 1 078 552 064 USD
Yield for 12 month -0.73 %
1Y
3Y
5Y
10Y
15Y
OPK
21.11.2021 - 28.11.2021

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida. Address: 4400 Biscayne Boulevard, Miami, FL, United States, 33137

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.99 USD

P/E Ratio

Dividend Yield

Financials OPK

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures OPK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+713 142 000 USD

Last Year

+863 495 000 USD

Current Quarter

+149 952 000 USD

Last Quarter

+183 638 000 USD

Current Year

+218 510 000 USD

Last Year

+318 127 000 USD

Current Quarter

+42 620 000 USD

Last Quarter

+84 659 000 USD
EBITDA -173 411 008 USD
Operating Margin TTM -44.79 %
Price to Earnings
Return On Assets TTM -8.20 %
PEG Ratio -2.87
Return On Equity TTM -3.04 %
Wall Street Target Price 3.99 USD
Revenue TTM 689 408 000 USD
Book Value 1.95 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -13.70 %
Dividend Yield
Gross Profit TTM 104 943 000 USD
Earnings per share -0.060 USD
Diluted Eps TTM -0.060 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 19.10 %
Profit Margin -5.66 %

Stock Valuation OPK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 64.52
Enterprise Value Revenue 1.63
Price Sales TTM 1.56
Enterprise Value EBITDA 7.46
Price Book MRQ 0.81

Technical Indicators OPK

For 52 Weeks

1.21 USD 2.04 USD
50 Day MA 1.33 USD
Shares Short Prior Month 31 662 082
200 Day MA 1.51 USD
Short Ratio 10.97
Shares Short 30 996 173
Short Percent 6.66 %